Skip to main content
Top
Published in: Journal of Gastroenterology 5/2011

01-05-2011 | Original Article—Alimentary Tract

Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis

Authors: Hiroshi Umemura, Akira Togawa, Kazuyuki Sogawa, Mamoru Satoh, Kaoru Mogushi, Motoi Nishimura, Kazuyuki Matsushita, Hiroshi Tanaka, Hirotaka Takizawa, Yoshio Kodera, Fumio Nomura

Published in: Journal of Gastroenterology | Issue 5/2011

Login to get access

Abstract

Background

Serum biomarkers currently available for gastric cancers are not sufficiently sensitive and specific.

Methods

We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MS) to generate comparative peptide profiles of serum samples obtained from gastric cancer patients (n = 81) and age- and sex-matched healthy controls (n = 66).

Results

Because of initial screening and further validation, we found that the intensities of a 2209 m/z MS peak were increased in the preoperative sera obtained from gastric cancer patients, and we identified this peak, a 2209 Da peptide, as a high molecular weight (HMW) kininogen fragment. Receiver operating characteristic analyses showed that the area under the curve (AUC) for the 2209 Da peptide (AUC = 0.715) was greater than those for conventional tumor markers (carcinoembryonic antigen AUC = 0.593, carbohydrate antigen 19-9 AUC = 0.527) used for the detection of stage I gastric cancers. Inverse correlations were observed between the levels of intact HMW kininogen and the 2209 Da peptide, suggesting that the upregulation of some protease activities is responsible for the overproduction of a kininogen fragment in gastric cancer patients.

Conclusions

Serum levels of the 2209 Da peptide identified in this study have a greater diagnostic ability than those of conventional tumor markers used for the early detection of gastric cancer.
Literature
1.
go back to reference Goodman KJ, Cockburn M. The role of epidemiology in understanding the health effects of Helicobacter pylori. Epidemiology. 2001;12:266–71.PubMedCrossRef Goodman KJ, Cockburn M. The role of epidemiology in understanding the health effects of Helicobacter pylori. Epidemiology. 2001;12:266–71.PubMedCrossRef
2.
go back to reference Wobbes T, Thomas CM, Segers MF, Nagengast FM. Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 TruQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992;69:2036–41.PubMedCrossRef Wobbes T, Thomas CM, Segers MF, Nagengast FM. Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 TruQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992;69:2036–41.PubMedCrossRef
3.
go back to reference Fernandez-Fernandez L, Tejero E, Tieso A, Rabadan L, Munoz M, Santos I. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19–9 and CA 72–4 in gastric cancer. Int Surg. 1996;81:400–2.PubMed Fernandez-Fernandez L, Tejero E, Tieso A, Rabadan L, Munoz M, Santos I. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19–9 and CA 72–4 in gastric cancer. Int Surg. 1996;81:400–2.PubMed
4.
go back to reference Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, et al. Evaluation of serum CEA and CA19–9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000;3:177–86.PubMedCrossRef Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, et al. Evaluation of serum CEA and CA19–9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000;3:177–86.PubMedCrossRef
5.
go back to reference Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267–75.PubMedCrossRef Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267–75.PubMedCrossRef
6.
go back to reference Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer. 2006;6:961–7.PubMedCrossRef Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer. 2006;6:961–7.PubMedCrossRef
7.
go back to reference Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem. 2006;52:1223–37.PubMedCrossRef Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem. 2006;52:1223–37.PubMedCrossRef
8.
go back to reference Davies HA. The ProteinChip System from Ciphergen: a new technique for rapid, micro-scale protein biology. J Mol Med. 2000;78:B29.PubMed Davies HA. The ProteinChip System from Ciphergen: a new technique for rapid, micro-scale protein biology. J Mol Med. 2000;78:B29.PubMed
9.
go back to reference Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, et al. The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2010;45:459–67.PubMedCrossRef Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, et al. The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2010;45:459–67.PubMedCrossRef
10.
go back to reference Nomura F, Tomonaga T, Sogawa K, Ohashi T, Nezu M, Sunaga M, et al. Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics. 2004;4:1187–94.PubMedCrossRef Nomura F, Tomonaga T, Sogawa K, Ohashi T, Nezu M, Sunaga M, et al. Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics. 2004;4:1187–94.PubMedCrossRef
11.
go back to reference Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, et al. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene. 2008;27:2810–22.PubMedCrossRef Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, et al. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene. 2008;27:2810–22.PubMedCrossRef
12.
go back to reference Zhang X, Leung SM, Morris CR, Shigenaga MK. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech. 2004;15:167–75.PubMed Zhang X, Leung SM, Morris CR, Shigenaga MK. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech. 2004;15:167–75.PubMed
13.
go back to reference Sogawa K, Satoh M, Kodera Y, Tomonaga T, Iyo M, Nomura F. A search for novel markers of alcohol abuse using magnetic beads and MALDI-TOF/TOF mass spectrometry. Proteomics Clin Appl. 2009;3:821–8.PubMedCrossRef Sogawa K, Satoh M, Kodera Y, Tomonaga T, Iyo M, Nomura F. A search for novel markers of alcohol abuse using magnetic beads and MALDI-TOF/TOF mass spectrometry. Proteomics Clin Appl. 2009;3:821–8.PubMedCrossRef
14.
go back to reference Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588–99.PubMedCrossRef Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588–99.PubMedCrossRef
15.
go back to reference Umemura H, Nezu M, Kodera Y, Satoh M, Kimura A, Tomonaga T, et al. Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta. 2009;406:179–80.PubMedCrossRef Umemura H, Nezu M, Kodera Y, Satoh M, Kimura A, Tomonaga T, et al. Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta. 2009;406:179–80.PubMedCrossRef
16.
go back to reference Umemura H, Kodera Y, Nomura F. Effects of humidity on the dried-droplet sample preparation for MALDI-TOF MS peptide profiling. Clin Chim Acta. 2010;411:2109–11.PubMedCrossRef Umemura H, Kodera Y, Nomura F. Effects of humidity on the dried-droplet sample preparation for MALDI-TOF MS peptide profiling. Clin Chim Acta. 2010;411:2109–11.PubMedCrossRef
17.
go back to reference Ebert MP, Meuer J, Wiemer JC, Schulz HU, Reymond MA, Traugott U, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res. 2004;3:1261–6.PubMedCrossRef Ebert MP, Meuer J, Wiemer JC, Schulz HU, Reymond MA, Traugott U, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res. 2004;3:1261–6.PubMedCrossRef
18.
go back to reference Ebert MP, Lamer S, Meuer J, Malfertheiner P, Reymond M, Buschmann T, et al. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res. 2005;4:586–90.PubMedCrossRef Ebert MP, Lamer S, Meuer J, Malfertheiner P, Reymond M, Buschmann T, et al. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res. 2005;4:586–90.PubMedCrossRef
19.
go back to reference Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, Hoffmann J, et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res. 2006;5:2152–8.PubMedCrossRef Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, Hoffmann J, et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res. 2006;5:2152–8.PubMedCrossRef
20.
go back to reference Su Y, Shen J, Qian H, Ma H, Ji J, Ma H, et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci. 2007;98:37–43.PubMedCrossRef Su Y, Shen J, Qian H, Ma H, Ji J, Ma H, et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci. 2007;98:37–43.PubMedCrossRef
21.
22.
23.
go back to reference Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–43.PubMedCrossRef Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–43.PubMedCrossRef
24.
go back to reference Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, et al. Serum pepsinogen and gastric cancer screening. Intern Med. 2007;46:261–6.PubMedCrossRef Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, et al. Serum pepsinogen and gastric cancer screening. Intern Med. 2007;46:261–6.PubMedCrossRef
25.
go back to reference Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271–84.PubMedCrossRef Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271–84.PubMedCrossRef
26.
go back to reference Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208:970–8.PubMedCrossRef Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ, et al. Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg. 2009;208:970–8.PubMedCrossRef
27.
go back to reference Roeise O, Sivertsen S, Ruud TE, Bouma BN, Stadaas JO, Aasen AO. Studies on components of the contact phase system in patients with advanced gastrointestinal cancer. Cancer. 1990;65:1355–9.PubMedCrossRef Roeise O, Sivertsen S, Ruud TE, Bouma BN, Stadaas JO, Aasen AO. Studies on components of the contact phase system in patients with advanced gastrointestinal cancer. Cancer. 1990;65:1355–9.PubMedCrossRef
28.
go back to reference Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95:543–50.PubMed Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95:543–50.PubMed
29.
go back to reference Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci USA. 2002;99:12224–9.PubMedCrossRef Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci USA. 2002;99:12224–9.PubMedCrossRef
30.
go back to reference Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol. 1992;116:465–76.PubMedCrossRef Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol. 1992;116:465–76.PubMedCrossRef
31.
go back to reference Kawasaki M, Maeda T, Hanasawa K, Ohkubo I, Tani T. Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo. J Biol Chem. 2003;278:49301–7.PubMedCrossRef Kawasaki M, Maeda T, Hanasawa K, Ohkubo I, Tani T. Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo. J Biol Chem. 2003;278:49301–7.PubMedCrossRef
32.
go back to reference Liu Y, Pixley R, Fusaro M, Godoy G, Kim E, Bromberg ME, et al. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene. 2009;28:2756–65.PubMedCrossRef Liu Y, Pixley R, Fusaro M, Godoy G, Kim E, Bromberg ME, et al. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene. 2009;28:2756–65.PubMedCrossRef
33.
go back to reference Fortin T, Salvador A, Charrier JP, Lenz C, Bettsworth F, Lacoux X, et al. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal Chem. 2009;81:9343–52.PubMedCrossRef Fortin T, Salvador A, Charrier JP, Lenz C, Bettsworth F, Lacoux X, et al. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal Chem. 2009;81:9343–52.PubMedCrossRef
34.
go back to reference Baechle D, Sparbier K, Dihazi H, Blaschke S, Mueller GA, et al. Towards stable diagnostic setups in clinical proteomics: absolute quantitation of peptide biomarkers using MALDI-TOF-MS. Proteomics Clin Appl. 2007;1:1280–4.CrossRef Baechle D, Sparbier K, Dihazi H, Blaschke S, Mueller GA, et al. Towards stable diagnostic setups in clinical proteomics: absolute quantitation of peptide biomarkers using MALDI-TOF-MS. Proteomics Clin Appl. 2007;1:1280–4.CrossRef
Metadata
Title
Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis
Authors
Hiroshi Umemura
Akira Togawa
Kazuyuki Sogawa
Mamoru Satoh
Kaoru Mogushi
Motoi Nishimura
Kazuyuki Matsushita
Hiroshi Tanaka
Hirotaka Takizawa
Yoshio Kodera
Fumio Nomura
Publication date
01-05-2011
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 5/2011
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-010-0369-3

Other articles of this Issue 5/2011

Journal of Gastroenterology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine